Baijin Life Science Holdings Limited (1466.HK) Announces 2026 Annual Results: Significant Losses, Capital Moves, and Strategic Developments
Key Financial Highlights and Investor-Relevant Developments
- Revenue dropped sharply by 34% year-on-year, from HK\$135.6 million to HK\$89.3 million.
- Gross profit plummeted 84%, from HK\$42 million to just HK\$6.7 million. Gross margin collapsed from 31% to 7.5%.
- Loss before income tax surged to HK\$43.1 million (vs. HK\$1.4 million loss last year), with loss attributable to shareholders ballooning to HK\$37.9 million (vs. HK\$0.3 million loss last year).
- Basic loss per share deteriorated to HK4.49 cents (vs. HK0.05 cent in 2025); diluted loss per share worsened to HK5.61 cents.
- Despite losses, net assets increased 23% to HK\$192.3 million due to share issuances and convertible bond conversion.
- Shareholders’ equity rose to HK\$185.2 million (from HK\$139.3 million).
- Current ratio decreased to 3.0 (from 4.6), indicating a tighter liquidity position.
Significant Corporate Actions and Shareholder-Relevant Issues
-
Major equity fundraising and dilution:
- Several tranches of new shares were issued during the year at HK\$0.48 per share, raising a total of approximately HK\$63.6 million in net proceeds.
- Convertible bond (fair value HK\$62.3 million) fully converted into 119.86 million shares, increasing the issued share capital to 932.25 million shares.
- Share dilution is a key concern for existing shareholders.
-
Board lot size reduction:
- Effective December 8, 2025, board lot size reduced from 32,000 to 8,000 shares, lowering entry cost for retail investors and potentially improving liquidity.
- No final dividend: Despite increased equity base and capital raises, the Board does not recommend any final dividend for the year, in line with sustained losses.
- Human resources and cost: Headcount increased to 84 (from 75), staff costs HK\$13.6 million (up from HK\$12.8 million), even as core business shrank.
Business Review and Strategy Shifts
-
Core businesses:
- Design and sales of jewellery products
- Real estate financial assets investments
- Sales of skincare products under the “FO” brand, and provision of scientific research, franchise licensing and consulting services
-
Strategic pivot towards medical and biotechnology:
- Development of self-operated medical service outlets, collaboration with large hospitals, and expansion into clinical cell therapy, circular RNA technology, and medical device distribution.
- Increased operational complexity and resource allocation to new business lines.
-
Disposal of non-core business:
- Exited from co-working business investment, with subsidiary sold for HK\$1 to an independent third party in July 2024.
-
Financial risks and outlook:
- Continued exposure to RMB and USD currency fluctuations; no major hedging in place but active monitoring.
- Bank borrowings increased to HK\$13.7 million, though interest rates on new borrowings are lower than the prior year.
- Significant capital commitments: HK\$11.25 million contracted for property, plant, and equipment, indicating ongoing investments despite losses.
- Management expects new strategic initiatives and sustained demand in the Chinese skincare market to eventually drive operational improvement.
Corporate Governance and Shareholder Information
- No CEO; executive director duties are shared among board members.
- All directors have fulfilled continuous professional development requirements.
- Sufficient public float maintained.
- No pre-emptive rights for shareholders under Cayman law; share capital changes can dilute existing holders.
- Shareholders are encouraged to provide feedback and make enquiries; the company has reviewed and found its communication policy effective.
Potential Price-Sensitive Issues
- Significant net loss and steep margin decline may put further pressure on the share price and investor sentiment.
- Large-scale share dilution from equity fundraising and convertible bond conversion could weigh on share price, especially as performance deteriorates.
- No dividend payout despite capital raising may disappoint yield-seeking investors.
- Board lot size reduction could increase trading liquidity and attract more retail participation, possibly boosting share turnover in the short term.
- Strategic shift and ongoing losses create uncertainties in the Group’s future earnings visibility; execution risk is high as the Group ventures into new, highly regulated areas.
Conclusion
Baijin Life Science Holdings is at a critical juncture with significant operational losses, aggressive capital raising, and a strategic shift towards medical and biotech ventures. While management is betting on long-term growth from its new business initiatives, current financials reflect a challenging transition period marked by share dilution, tighter liquidity, and no immediate return to profitability.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult with professional advisers before making investment decisions. Baijin Life Science Holdings’ future performance may differ materially from past results or forward-looking statements contained herein.
